Moderna Inc (NASDAQ: MRNA) kicked off on Monday, up 2.48% from the previous trading day, before settling in for the closing price of $27.46. Over the past 52 weeks, MRNA has traded in a range of $23.15-$153.56.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 121.86% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -8.37%. With a float of $342.49 million, this company’s outstanding shares have now reached $387.00 million.
In an organization with 5800 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 52.55%, operating margin of -118.04%, and the pretax margin is -107.82%.
Moderna Inc (MRNA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Moderna Inc is 11.44%, while institutional ownership is 72.21%. The most recent insider transaction that took place on Mar 03 ’25, was worth 5,004,318. In this transaction Chief Executive Officer of this company bought 160,314 shares at a rate of $31.22, taking the stock ownership to the 9,210,686 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Director bought 31,620 for $31.76, making the entire transaction worth $1,004,251. This insider now owns 312,027 shares in total.
Moderna Inc (MRNA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.81 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.91% during the next five years compared to -42.94% drop over the previous five years of trading.
Moderna Inc (NASDAQ: MRNA) Trading Performance Indicators
Take a look at Moderna Inc’s (MRNA) current performance indicators. Last quarter, stock had a quick ratio of 4.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.72, a number that is poised to hit -2.96 in the next quarter and is forecasted to reach -7.45 in one year’s time.
Technical Analysis of Moderna Inc (MRNA)
Let’s dig in a bit further. During the last 5-days, its volume was 9.79 million. That was inferior than the volume of 11.56 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 50.75%. Additionally, its Average True Range was 1.63.
During the past 100 days, Moderna Inc’s (MRNA) raw stochastic average was set at 22.43%, which indicates a significant decrease from 57.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.16% in the past 14 days, which was lower than the 73.48% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.37, while its 200-day Moving Average is $42.45. However, in the short run, Moderna Inc’s stock first resistance to watch stands at $29.00. Second resistance stands at $29.86. The third major resistance level sits at $30.54. If the price goes on to break the first support level at $27.47, it is likely to go to the next support level at $26.79. Assuming the price breaks the second support level, the third support level stands at $25.93.
Moderna Inc (NASDAQ: MRNA) Key Stats
The company with the Market Capitalisation of 10.88 billion has total of 386,742K Shares Outstanding. Its annual sales at the moment are 3,236 M in contrast with the sum of -3,561 M annual income. Company’s last quarter sales were recorded 108,000 K and last quarter income was -971,000 K.
